Home | Emerging Regions
The iCMLf is committed to improving the quality of care for CML patients internationally. We have set as one of our first priorities a support program for clinicians working in the emerging economic regions who may not have easy access to appropriate monitoring assays and are likely to face difficulties in their efforts to update their knowledge and skills regarding best practice for CML patients. Our initial program is designed to establish a supportive relationship between international CML centres of excellence and clinicians in developing regions who have a significant commitment to CML patients. These iCMLf projects are Emerging Regions Support and Partnership (ERSAP) Programs.
This program is designed for clinicians from emerging economic regions with a specific interest in the treatment of CML and a significant CML patient load. The program enhances clinical knowledge and skills in the treatment of CML through preceptorships at internationally renowned CML centres. Participants of the program become part of the clinical team at the host site for the duration of the preceptorship, undertaking seminars and laboratory work where appropriate.
This Virtual Education Program offers a series of webcast presentations from leading hematologists. These presentations provide updated information on treatment advances and best practice management of CML, including disease monitoring and new therapies. The sessions specifically address issues of CML care in countries with limited access to monitoring and supplemental treatments. To make the program also accessible to clinicians from non English-speaking emerging economic regions the Virtual Education Program is also available in French and Spanish modules.
The iCMLf Diagnosis and Testing Program provides diagnostic testing and ultimately disease monitoring for CML patients in emerging economic countries where this is limited or not currently available. Many hospitals in developing countries do not have the capability to confirm the diagnosis of CML either by cytogenetics or by molecular tests, which results in patients not being able to access the medication available to enhance and extend their quality of life. Moreover continued monitoring is essential to detect any progression of the disease that in many cases can be halted with available therapy. Through the iCMLf Diagnosis and Testing Program the iCMLf will set up facilities at a local level to either bring high quality testing to the patient, or to develop a low cost strategy for sending patient samples to a central reference laboratory for testing.
Read more about the programs here: